{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000043","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.715810+00:00","generated_at":"2026-06-09T00:23:30.335357+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aurinia Q3 net product revenue $40.8M (+60% YoY); narrows FY2023 guidance to $155-160M","bullets":["Net product revenue $40.8M in Q3, up 60% YoY; 9-month net product revenue $116.2M (+55%).","Narrowed FY2023 net product revenue guidance to $155-160M from prior range.","Net loss $13.4M ($0.09/share) vs $9.0M ($0.06/share) in Q3 2022; 9-month net loss improved to $51.1M from $82.1M.","Patients on LUPKYNIS at Sept 30: ~1,939 (+43% YoY); 436 PSFs added in Q3 (+17%).","Received $10M milestone from Otsuka for European pricing and reimbursement in three major markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000043","json":"https://secwatch.observer/filing/0001600620-23-000043.json","markdown":"https://secwatch.observer/filing/0001600620-23-000043.md","text":"https://secwatch.observer/filing/0001600620-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/auph-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:23:30.335357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70e1eead1f47ead7e556aa2d7579040c4f397bab","claim":"Aurinia Pharmaceuticals Inc. reported three months ended September 30, 2023 results: revenue $54.5 million.","evidence_excerpt":"Total net revenue was $54.5 million for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$54.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9454df8e2af3d266c85d1b6c4741263bf6f60083","claim":"Aurinia Pharmaceuticals Inc. reported nine months ended September 30, 2023 results: revenue $130.4 million.","evidence_excerpt":"Total net revenue was $130.4 million for the nine months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Revenue","value":"$130.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}